Your Medication Isn't Working. Your Genes May Be Metabolizing It Wrong.

CYP2D6 is one of your liver’s most important drug-processing enzymes. It’s responsible for metabolizing roughly 25% of all medications on the market, including antidepressants like sertraline and paroxetine, opioid painkillers, beta-blockers for heart rhythm, and even codeine from cough syrup. This single enzyme is the gatekeeper for whether these drugs reach therapeutic levels or accumulate to toxic levels.

Here’s where it gets critical: CYP2D6 has more variants than almost any other drug-metabolism gene. Common variants include *2, *4, *10, and *17, which reduce enzyme activity to varying degrees. Poor metabolizers, those with two copies of loss-of-function variants, make up roughly 7-10% of people with European ancestry. Poor metabolizers can accumulate drug levels that are four, five, even ten times higher than expected, turning a standard dose into a toxic burden. On the flip side, ultra-rapid metabolizers with gene duplications burn through medications so quickly they never reach therapeutic levels.

If you’re a poor metabolizer taking a standard dose of sertraline for depression, you might experience side effects like tremor, nausea, dizziness, or emotional blunting within days at a dose that barely helps others. If you’re taking codeine for pain and you’re a poor metabolizer, the drug simply won’t work. If you’re ultra-rapid, you’ll feel nothing at all.

CYP2C19 metabolizes clopidogrel (Plavix), a drug that prevents blood clots after heart attacks or stents, and also breaks down many antidepressants and proton pump inhibitors (PPIs) that reduce stomach acid. It seems like a routine enzyme, but the stakes here are genuinely life-or-death.

Clopidogrel is what’s called a prodrug: your liver must activate it to make it work. Poor metabolizers, carrying *2 or *3 variants, account for roughly 2-15% of the population depending on ancestry, and in these individuals, clopidogrel remains inactive and provides zero antiplatelet benefit. Someone recovering from a heart attack on an inactive drug is at extreme risk of another clot. Ultra-rapid metabolizers, on the other hand, activate clopidogrel so quickly they have elevated bleeding risk. It’s not a dose adjustment problem. It’s a complete mismatch between drug and enzyme.

The same gene also affects antidepressants. A poor metabolizer on a standard dose of an SSRI or tricyclic antidepressant might feel relief after a week, while ultra-rapid metabolizers feel nothing or develop side effects because the drug is cleared before it can work.

CYP2C9 metabolizes warfarin, the gold-standard blood thinner for atrial fibrillation and clot prevention, as well as NSAIDs like ibuprofen and naproxen, and some statins. Warfarin has an extraordinarily narrow therapeutic window: too little and you don’t prevent clots; too much and you bleed internally.

Poor metabolizers of CYP2C9, those with *2 or *3 variants, make up roughly 5-10% of people with European ancestry. Poor metabolizers clear warfarin so slowly that standard doses cause bleeding, even at doses that work fine for others. A poor metabolizer taking the average warfarin dose prescribed in primary care might end up with an INR (blood clotting measure) of 8 or 9, far above the therapeutic target of 2-3, leading to nosebleeds, bruising, blood in urine, or catastrophic internal bleeding. Conversely, ultra-rapid metabolizers might need double or triple the standard dose to achieve any anticoagulation at all.

You’ll notice easy bruising, bleeding gums, blood in stool, or excessive bleeding from a minor cut. Your doctor might think you’re overdoing it with the medication and lower your dose, only to have you clot. It’s a maddening cycle that ends with genetic testing.

VKORC1 is the actual target that warfarin attacks. It encodes the vitamin K epoxide reductase, the enzyme that recycles vitamin K so your body can keep making clotting factors. Warfarin blocks this recycling. VKORC1 variants, particularly the -1639G>A SNP, determine how sensitive this system is to warfarin’s interference.

Roughly 40% of people with European ancestry carry the A allele at this position, which means their vitamin K recycling system is less efficient, making them highly sensitive to warfarin and requiring significantly lower doses. Someone with two A alleles might need 3-5 mg of warfarin daily to reach therapeutic INR, while someone with two G alleles might need 8-10 mg for the same effect. It’s not about liver function. It’s pure pharmacogenomics.

You might start warfarin at the standard 5 mg dose only to find your INR shoots to 5 or 6 within days, causing bleeding. Your doctor lowers the dose, overshoots the other direction, and you’re back in the clinic. With VKORC1 testing, you’d know your sensitivity upfront and start at the right dose.

SLCO1B1 encodes a transporter protein that actively pumps statins (cholesterol-lowering drugs like simvastatin, pravastatin, and atorvastatin) into liver cells where they can work. Without this transporter, statins remain circulating in your bloodstream at elevated levels, increasing the risk of muscle damage.

The *5 variant, marked by the rs4149056 C allele, is present in roughly 15% of the population and reduces the efficiency of this hepatic transporter, causing statins to accumulate in your blood instead of being taken up by your liver where they’re supposed to work. People carrying this variant on standard simvastatin doses are at substantially elevated risk of myopathy: muscle pain, weakness, and in severe cases, rhabdomyolysis (breakdown of muscle tissue that can damage kidneys).

You might start a statin for high cholesterol and within days develop muscle soreness, fatigue, and pain so severe you can barely walk. Standard bloodwork doesn’t explain it. Your doctor might blame age or overexertion. But if you carry the SLCO1B1 *5 variant, your liver simply isn’t taking up the statin efficiently enough, and you need either a much lower dose or a different statin class entirely.

TPMT metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine, which are used to suppress the immune system in autoimmune diseases like Crohn’s disease, ulcerative colitis, and lupus, and also used in some cancer chemotherapy protocols. These drugs are toxic by design: they’re meant to kill rapidly dividing cells or suppress immune overactivity. The dose-toxicity line is razor-thin.

Poor metabolizers of TPMT, those with two copies of loss-of-function variants, make up roughly 0.3% of the population. Poor metabolizers accumulate thiopurine metabolites to lethal levels, causing severe bone marrow suppression that can be fatal. Even heterozygous carriers (one loss-of-function variant) are at substantially elevated risk of toxicity. Standard dosing guidelines are based on people with normal TPMT activity. Giving a poor metabolizer the standard dose is like giving them chemotherapy by accident.

You might start azathioprine for your inflammatory bowel disease and within weeks develop severe anemia, low white blood cell count, infections you can’t fight off, or uncontrollable bleeding. Your doctor might think you’ve developed a new infection or complication, when actually it’s bone marrow destruction from drug accumulation. TPMT testing isn’t optional here: it’s a safety requirement.